SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sealbond Ltd
(Last) (First) (Middle)
2 DAI FU STREET,
TAI PO INDUSTRIAL ESTATE
(Street)
NEW TERRITORIES K3
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) X Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2025 C(1) 21,610,950 A (1) 21,822,333 D(2)
Common Stock 11/21/2025 C(1) 2,842,638 A (1) 2,842,638 I(3) By Conjoint Inc.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock (1) 11/21/2025 C(1) 2,161.095(4) (1) (1) Common Stock 21,610,950 $0 0 D(2)
Series A-1 Preferred Stock (1) 11/21/2025 C(1) 284.2638 (1) (1) Common Stock 2,842,638 $0 0 I(3) By Conjoint Inc.
1. Name and Address of Reporting Person*
Sealbond Ltd
(Last) (First) (Middle)
2 DAI FU STREET,
TAI PO INDUSTRIAL ESTATE
(Street)
NEW TERRITORIES K3
(City) (State) (Zip)
1. Name and Address of Reporting Person*
Conjoint Inc.
(Last) (First) (Middle)
2 DAI FU STREET,
TAI PO INDUSTRIAL ESTATE
(Street)
NEW TERRITORIES K3
(City) (State) (Zip)
1. Name and Address of Reporting Person*
CK Life Sciences Intl (Holdings) Inc
(Last) (First) (Middle)
2 DAI FU STREET,
TAI PO INDUSTRIAL ESTATE
(Street)
NEW TERRITORIES K3
(City) (State) (Zip)
Explanation of Responses:
1. On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.
2. Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
3. Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.
4. Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
Remarks:
Mr. Yu Ying Choi Alan Abel ("Mr. Yu"), the Deputy Chairman of CKLS, and Dr. Toh Kean Meng Melvin ("Dr. Toh"), the Vice President and Chief Scientific Officer and Executive Director of CKLS, have been appointed to the board of directors of the Issuer, and each of Mr. Yu and Dr. Toh have been deputized to represent the Reporting Person on the board of directors. By virtue of Mr. Yu and Dr. Toh's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Mr. Yu and Dr. Toh have filed separate Section 16 reports disclosing securities of the Issuer that each may respectively be deemed to beneficially own for Section 16 purposes.
/s/ Wong Wun Lam, Director of Sealbond Limited 11/25/2025
/s/ Yu Ying Choi Alan Abel, Director of Conjoint Inc. 11/25/2025
/s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc. 11/25/2025
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.